KalVista Pharmaceuticals’ (KALV) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV) in a research report released on Friday morning, MarketBeat Ratings reports. The firm currently has a $27.00 price objective on the specialty pharmaceutical company’s stock, down from their previous price objective of $37.00.

KALV has been the subject of a number of other research reports. JonesTrading downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday. Leerink Partners downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Citizens Jmp downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Needham & Company LLC downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, Stifel Nicolaus boosted their target price on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Three equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $30.60.

KalVista Pharmaceuticals Price Performance

Shares of KalVista Pharmaceuticals stock traded down $0.01 during trading hours on Friday, reaching $26.65. The stock had a trading volume of 5,118,369 shares, compared to its average volume of 5,155,986. The stock’s 50 day moving average is $18.45 and its 200 day moving average is $15.72. The firm has a market capitalization of $1.37 billion, a PE ratio of -6.75 and a beta of -0.40. KalVista Pharmaceuticals has a twelve month low of $9.83 and a twelve month high of $26.76. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18.

Insider Buying and Selling at KalVista Pharmaceuticals

In related news, major shareholder Venrock Healthcare Capital Par sold 39,986 shares of the company’s stock in a transaction dated Thursday, March 26th. The shares were sold at an average price of $18.28, for a total transaction of $730,944.08. Following the completion of the sale, the insider owned 5,089,354 shares of the company’s stock, valued at approximately $93,033,391.12. This represents a 0.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Paul K. Audhya sold 2,686 shares of the company’s stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $20.22, for a total transaction of $54,310.92. Following the sale, the insider directly owned 142,547 shares of the company’s stock, valued at approximately $2,882,300.34. This represents a 1.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 263,969 shares of company stock valued at $4,536,178. Corporate insiders own 4.30% of the company’s stock.

Institutional Trading of KalVista Pharmaceuticals

Several large investors have recently bought and sold shares of KALV. Tudor Investment Corp ET AL purchased a new stake in KalVista Pharmaceuticals during the 3rd quarter valued at about $24,360,000. Vestal Point Capital LP grew its stake in KalVista Pharmaceuticals by 152.0% during the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after acquiring an additional 1,140,000 shares in the last quarter. Parkman Healthcare Partners LLC grew its stake in KalVista Pharmaceuticals by 155.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after acquiring an additional 1,055,940 shares in the last quarter. Ameriprise Financial Inc. grew its stake in KalVista Pharmaceuticals by 2,258.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock valued at $10,685,000 after acquiring an additional 905,053 shares in the last quarter. Finally, Elmind Capital LP purchased a new stake in shares of KalVista Pharmaceuticals in the 4th quarter valued at approximately $12,941,000.

Key Headlines Impacting KalVista Pharmaceuticals

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Chiesi Group agreed to acquire KalVista for $27.00 per share in cash (~$1.9B), creating a clear-cash exit and explaining the stock’s run-up on the takeover premium. Chiesi to buy KalVista in $1.9B deal for rare disease drug
• Neutral Sentiment: HC Wainwright reaffirmed a “neutral” rating and cut its price target to $27 from $37, signaling limited upside vs. the deal price but keeping stance unchanged. Benzinga
• Negative Sentiment: Several brokerages (Needham, JonesTrading, Leerink, Citizens Jmp) downgraded KalVista from buy/strong-buy to hold, reducing buy-side analyst enthusiasm and potentially limiting upward momentum ahead of/around deal close. Zacks
• Negative Sentiment: Shareholder-law firms Kahn Swick & Foti and Halper Sadeh announced investigations into whether the $27 per share consideration and the sale process are fair, introducing legal and timing risk that could complicate or delay the transaction and create downside volatility. KalVista Investor Alert: Kahn Swick & Foti Investigates Halper Sadeh investigation report
• Neutral Sentiment: Elevated trading volume and the stock trading near its 52‑week high reflect deal-driven activity; with the $27 cash offer effectively setting a takeover price, remaining movement will hinge on deal completion timing and any litigation or regulatory hurdles. (See aggregated news coverage.) MSN coverage

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.